Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy

British Journal of Cancer

Volumn 75, Issue 3, 1997, Pages 408-412

  Body, J J ^a,c   Dumon, J C ^a   Gineyts, E ^b   Delmas, P D ^d  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c JULES BORDET INSTITUTE   (Belgium)

^d NONE

Author keywords

Bisphosphonate; Bone metastases; Bone resorption; Breast cancer; Markers

Indexed keywords

ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; CALCIUM; COLLAGEN TYPE 1; DEOXYPYRIDINOLINE; HYDROXYPROLINE; PAMIDRONIC ACID; PYRIDINOLINE;

ADULT; AGED; ARTICLE; BONE MATRIX; BONE METASTASIS; BONE TURNOVER; BREAST CANCER; CALCIUM URINE LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COLLAGEN DEGRADATION; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROXYPROLINE URINE LEVEL; OSTEOLYSIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0031033408     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.66     Document Type: Article

References (19)

1. Averbuch SD (1493) New bisphosphonates in the treatment of bone metastases. Cancer 72: 3443-3452
2. Body JJ (1992) Metastatic bone disease: clinical and therapeutic aspects. Bone 13: S57-S62
3. Body JJ (1993) Medical treatment of tumor-induced hypercalcemia and tumor-induced osteolysis: challenges tor future research. Supp Care Cancer 1: 26-33
4. Body JJ and Delmas PD (1992) Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hypercalcemia. J Clin Endocrinol Metabol 74: 471-475
5. Body JJ, Pot M, Borkowski A, Sculier JP and Klastersky J (1987) A dose-response study of aminohydroxypropylidene bisphosphonate in tumor-associated hypercalcemia. Am J Med 82: 957-963
6. Body JJ, Dumon JC, Seraj F and Cleeren A (1992) Recovery of parathyroid hormone secretion during correction of tumor-associated hypercalcemia. J Clin Endocrinol Metab 74: 1385-1388
7. Body JJ, Dumon JC, Piccart M and Ford J (1995) Intravenous pamidronate in patients with tumor-induced osteolysis: a biochemical dose-response study. J Bone Miner Res 10: 1191-1196
8. Bonde M, Qvist P, Fledelius C, Riis BJ and Christiansen C (1994) Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 40: 2022-2025
9. Coleman RE, Mashiter G, Whitaker KB, Moss DW, Rubens RD and Fogelman I (1988) Bone scan flare predicts successful systemic therapy for bone metastases. J Nucl Med 29: 1354-1359
10. Coleman RE, Houston S, James I, Rodger A, Rubens RD, Leonard RCF and Ford J (1992) Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease. Br J Cancer 65: 766-768
11. Delmas PD (1990) Biochemical markers of bone turnover tor the clinical assessment of metabolic bone disease. Endocrinol Metab Clin North Am 19: 1-18
12. Delmas PD, Schlemmer A, Gineyts K, Riis B and Christiansen C (1991) Urinary excretion of pyridinoline crosslinks correlate with bone turnover measured on iliac crest bone biopsy in patients with vertebral osteoporosis. J Bone Miner Res 6: 639-644
13. Dumon JC and Body JJ (1995) Circulating osteocalcin in hypercalcemic cancer patients: a comparative evaluation of two immunoassays. Diagn Oncol 1: 170-173
14. Garnero P, Gineyts E, Riou JP and Delmas PD (1994) Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab 79: 780-785
15. Lipton A, Demers F, Daniloff Y, Curley F, Hamilton C, Harvey H, Witters L, Seaman J, Van Der Giessen R and Seyedin S (1993) Increased urinary excretion of pyridinium cross-links in cancer patients. Clin Chem 39: 614-618
16. Niell HB, Palmieri GM, Neely CL, Maxwell TA, Hopkins SC and Soloway MS (1983) Total, dialyzable, and nondialyzable postabsorptive hydroxyproline. Values in patients with cancer. Arch Intern Med 143: 1925-1927
17. Ralston SH (1992) Medical management of hypercalcemia. Br J Clin Pharmacol 34: 11-20
18. Uelbelhart D, Gineyts E, Chapuy MC and Delmas PD (1990) Urinary excretion of pyridinium crosslinks, a new marker of bone resorption in metabolic bone disease. Bone Miner 8: 87-96
19. Uebelhart D, Schlemmer A, Johansen JS, Gineyts E, Christiansen C and Delmas PD (1991) Effect of menopause and estrogen treatment on the urinary excretion of pyridinium crosslinks. J Clin Endocrinol Metab 72: 367-373